TAO Synergies (TAOX) Equity Income (2024)
TAO Synergies' (TAOX) quarterly Equity Income came in at -$14050.0 in Q4 2024, down 16.84% quarter-over-quarter from -$12025.0 in Q3 2024.
Powered by 
Analysis
TAO Synergies (TAOX) Equity Income (2024) Analysis & Trends
TAO Synergies (TAOX) has reported Equity Income for 1 consecutive years, with -$14050.0 the latest figure, recorded in Q4 2024.
- For the quarter ending Q4 2024, Equity Income changed N/A year-over-year to -$14050.0; the trailing twelve-month figure through Dec 2024 stood at -$44525.0 (changed N/A YoY), and the FY2024 full-year result was -$44525.0, changed N/A from the prior year.
- Equity Income fell to -$14050.0 in Q4 2024 per TAOX's latest filing, from -$12025.0 in the prior quarter.
- Across five years, Equity Income topped out at -$8600.0 in Q1 2024 and bottomed at -$14050.0 in Q4 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Equity Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 212.35 Bn | 198.36 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 181.19 Bn | 178.01 Bn | 6.22 Bn | - |
| 3 | Vertex Pharmaceuticals | 132.48 Bn | 124.62 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 82.59 Bn | 74.60 Bn | 3.93 Bn | - |
| 5 | Argenx Se | 61.45 Bn | 56.27 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.89 Bn | 49.75 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 34.21 Bn | 30.90 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.38 Bn | 30.10 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 29.81 Bn | 29.81 Bn | 1.16 Mn | - |
| 10 | TAO Synergies | 30.41 Mn | 30.41 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2024 | -14,050.00 |
| Sep 30, 2024 | -12,025.00 |
| Jun 30, 2024 | -9,850.00 |
| Mar 31, 2024 | -8,600.00 |